Advanced search
Publication Cover
Future Cardiology Volume 6, 2010 - Issue 3
Submit an article Journal homepage
87
Views
0
CrossRef citations to date
0
Altmetric
Special Report

Point-of-care Testing for Assessment of Adequacy of Oral Antiplatelet Therapy in Patients With Cardiovascular Disease

Magdalena Sobieraj-Teague1 Hamilton Health Sciences McMaster UniversityHamiltonOntarioL8L 2X2CanadaCorrespondence[email protected]
&
John W Eikelboom1 Hamilton Health Sciences McMaster UniversityHamiltonOntarioL8L 2X2Canada
Pages 289-299 | Published online: 12 May 2010

Bibliography

  • Antithrombotic Trialists‘ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324(7329), 71–86 (2002).
  • Johnson ES , LanesSF, WentworthCE 3rd, Satterfield MH, Abebe BL, Dicker LW: A metaregression analysis of the dose-response effect of aspirin on stroke. Arch. Intern. Med., 159(11), 1248–1253 (1999).
  • Burch JW , StanfordN, MajerusPW: Inhibition of platelet prostaglandin synthetase by oral aspirin.J. Clin. Invest., 61(2), 314–319 (1978).
  • Patrignani P , FilabozziP, PatronoC: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.J. Clin. Invest., 69(6), 1366–1372 (1982).
  • Smith SC et al. Jr, Allen J, Blair SN : AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J. Am. Coll. Cardiol., 47(10), 2130–2139 (2006).
  • Becker RC , MeadeTW, BergerPBet al.: The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest, 133(6 Suppl.), 776S–814S (2008).
  • Moffat KA , Ledford-KraemerMR, NicholsWL, HaywardCP: Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association.Thromb. Haemost., 93(3), 549–553 (2005).
  • Steinhubl SR , TalleyJD, BradenGAet al.: Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.Circulation, 103(21), 2572–2578 (2001).
  • Angiolillo DJ : Variability in responsiveness to oral antiplatelet therapy.Am. J. Cardiol., 103(3 Suppl.), 27A–34A (2009).
  • Wang TH , BhattDL, TopolEJ: Aspirin and clopidogrel resistance: an emerging clinical entity.Eur. Heart J., 27(6), 647–654 (2006).
  • Krasopoulos G , BristerSJ, BeattieWS, BuchananMR: Aspirin ‘resistance‘ and risk of cardiovascular morbidity: systematic review and meta-analysis.BMJ, 336(7637), 195–198 (2008).
  • Snoep JD , HovensMM, EikenboomJC, van der Bom JG, Huisman MV: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med., 167(15), 1593–1599 (2007).
  • Sofi F , MarcucciR, GoriAM, AbbateR, GensiniGF: Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events – a meta-analysis.Int. J. Cardiol., 128(2), 166–171 (2008).
  • Crescente M , Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G: Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb. Haemost., 99(1), 14–26 (2008).
  • Snoep JD , HovensMM, EikenboomJC, van der Bom JG, Jukema JW, Huisman MV: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J., 154(2), 221–231 (2007).
  • Jakubowski JA , PayneCD, LiYGet al.: The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.Thromb. Haemost., 99(2), 409–415 (2008).
  • Malinin A , PokovA, SwaimL, KotobM, SerebruanyV: Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.Methods Find. Exp. Clin. Pharmacol., 28(5), 315–322 (2006).
  • van Werkum JW , van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM: A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J. Thromb. Haemost., 4(11), 2516–2518 (2006).
  • Smith JW , SteinhublSR, LincoffAMet al.: Rapid platelet-function assay: an automated and quantitative cartridge-based method.Circulation, 99(5), 620–625 (1999).
  • Wheeler GL , BradenGA, SteinhublSRet al.: The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.Am. Heart J., 143(4), 602–611 (2002).
  • von Beckerath N , Pogatsa-MurrayG, WieczorekA, SibbingD, SchomigA, KastratiA: Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness.Thromb. Haemost., 95(5), 910–911 (2006).
  • Chen WH , LeePY, NgWet al.: Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention.Am. J. Cardiol., 96(6), 760–763 (2005).
  • Chen WH , LeePY, NgW, TseHF, LauCP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.J. Am. Coll. Cardiol., 43(6), 1122–1126 (2004).
  • Marcucci R , GoriAM, PanicciaRet al.: Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.Circulation, 119(2), 237–242 (2009).
  • Patti G , NuscaA, MangiacapraF, GattoL, D‘AmbrosioA, Di Sciascio G: Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty – Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol., 52(14), 1128–1133 (2008).
  • Price MJ , EndemannS, GollapudiRRet al.: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.Eur. Heart J., 29(8), 992–1000 (2008).
  • Favaloro EJ : Clinical utility of the PFA-100.Semin. Thromb. Hemost., 34(8), 709–733 (2008).
  • Paniccia R , AntonucciE, GoriAMet al.: Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients.J. Thromb. Haemost., 5(9), 1839–1847 (2007).
  • Geiger J , TeichmannL, GrossmannRet al.: Monitoring of clopidogrel action: comparison of methods.Clin. Chem., 51(6), 957–965 (2005).
  • Kotzailias N , ElwischgerK, SychaTet al.: Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients.J. Stroke Cerebrovasc. Dis., 16(5), 199–202 (2007).
  • Reny JL , De Moerloose P, Dauzat M, Fontana P: Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J. Thromb. Haemost., 6(3), 444–450 (2008).
  • Crescente M , Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C: PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients. Thromb. Haemost., 99(6), 1129–1131 (2008).
  • van Werkum JW , KleibeukerM, PostmaSet al.: A comparison between the Plateletworks®-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel.Int. J. Cardiol. doi:10.1016/j.ijcard.2008.10.046 (2008) (Epub ahead of print).
  • Craft RM , ChavezJJ, SniderCC, MuenchenRA, CarrollRC: Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients.J. Lab. Clin. Med., 145(6), 309–315 (2005).
  • White MM , KrishnanR, KueterTJ, JacoskiMV, JenningsLK: The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.J. Thromb. Thrombolysis, 18(3), 163–169 (2004).
  • Ray MJ , WaltersDL, BettN, CameronJ, WoodP, AroneyC: Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention.Catheter. Cardiovasc. Interv., 62(2), 150–154 (2004).
  • Craft RM , ChavezJJ, BreseeSJ, WorthamDC, CohenE, CarrollRC: A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation.J. Lab. Clin. Med., 143(5), 301–309 (2004).
  • Swallow RA , AgarwalaRA, DawkinsKD, CurzenNP: Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?.Platelets, 17(6), 385–392 (2006).
  • Tantry US , BlidenKP, GurbelPA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation.J. Am. Coll. Cardiol., 46(9), 1705–1709 (2005).
  • Bliden KP , DiChiaraJ, TantryUS, BassiAK, ChagantiSK, GurbelPA: Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?.J. Am. Coll. Cardiol., 49(6), 657–666 (2007).
  • Osende JI , FusterV, LevEIet al.: Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition.Circulation, 103(11), 1488–1491 (2001).
  • Shenkman B , SchneidermanJ, TamarinI, Kotev-EmethS, SavionN, VaronD: Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods.Thromb. Res., 102(4), 311–317 (2001).
  • Hankey GJ , EikelboomJW: Aspirin resistance.BMJ, 328(7438), 477–479 (2004).
  • Maree AO , FitzgeraldDJ: Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.Circulation, 115(16), 2196–2207 (2007).
  • Nguyen TA , DiodatiJG, PharandC: Resistance to clopidogrel: a review of the evidence.J. Am. Coll. Cardiol., 45(8), 1157–1164 (2005).
  • Lev EI , PatelRT, MareshKJet al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.J. Am. Coll. Cardiol., 47(1), 27–33 (2006).
  • Bonello L , Camoin-JauL, ArmeroSet al.: Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.Am. J. Cardiol., 103(1), 5–10 (2009).
  • Angiolillo DJ , ShoemakerSB, DesaiBet al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.Circulation, 115(6), 708–716 (2007).
  • Angiolillo DJ , CostaMA, ShoemakerSBet al.: Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.Am. J. Cardiol., 101(4), 440–445 (2008).
  • Cuisset T , FrereC, QuiliciJet al.: Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.J. Am. Coll. Cardiol., 48(7), 1339–1345 (2006).
  • Gurbel PA , BlidenKP, HayesKM, YohoJA, HerzogWR, TantryUS: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.J. Am. Coll. Cardiol., 45(9), 1392–1396 (2005).
  • Bonello L , Camoin-JauL, ArquesSet al.: Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.J. Am. Coll. Cardiol., 51(14), 1404–1411 (2008).
  • Angiolillo DJ , CapranzanoP, GotoSet al.: A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.Eur. Heart J., 29(18), 2202–2211 (2008).
  • Jeong YH , LeeSW, ChoiBRet al.: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.J. Am. Coll. Cardiol., 53(13), 1101–1109 (2009).
  • Storey RF , HustedS, HarringtonRAet al.: Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.J. Am. Coll. Cardiol., 50(19), 1852–1856 (2007).
  • Brandt JT , PayneCD, WiviottSDet al.: A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.Am. Heart J., 153(1), 66 E69–E16 (2007).
  • Jakubowski JA , PayneCD, LiYGet al.: A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.Thromb. Haemost., 99(1), 215–222 (2008).
  • Wallentin L , VarenhorstC, JamesSet al.: Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.Eur. Heart J., 29(1), 21–30 (2008).
  • Cuisset T , FrereC, QuiliciJet al.: Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.JACC Cardiovasc. Interv., 1(6), 649–653 (2008).
  • Michelson AD , CattaneoM, EikelboomJWet al.: Aspirin resistance: position paper of the Working Group on Aspirin Resistance.J. Thromb. Haemost., 3(6), 1309–1311 (2005).
  • Smith SC et al. Jr, Feldman TE, Hirshfeld JW Jr : ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention – summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation, 113(1), 156–175 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.